Dec 07, 2020 8:00am EST SCYNEXIS Announces FDA Acceptance and Priority Review of New Drug Application for Oral Ibrexafungerp for the Treatment of Vaginal Yeast Infections
Nov 06, 2020 8:44am EST SCYNEXIS Reports Third Quarter 2020 Financial Results and Provides Company Update
Oct 21, 2020 8:30am EDT SCYNEXIS to Present Data Supporting the Efficacy of Ibrexafungerp Against Invasive Fungal Infections at IDWeek 2020
Oct 14, 2020 8:30am EDT SCYNEXIS Announces Submission of New Drug Application to the U.S. Food and Drug Administration for Oral Ibrexafungerp for the Treatment of Vaginal Yeast Infection
Oct 12, 2020 8:30am EDT SCYNEXIS to Present Two Posters Highlighting Ibrexafungerp for the Treatment of Vaginal Yeast Infection at the 23rd Annual Premier Women's Healthcare Virtual Conference
Sep 10, 2020 8:38am EDT SCYNEXIS to Participate in H.C. Wainwright Conference and Maxim’s Antifungal Webinar
Aug 13, 2020 8:00am EDT SCYNEXIS Announces Presentations at 2020 IDSOG Virtual Annual Meeting Highlighting Ibrexafungerp’s Potential for the Treatment of Vulvovaginal Candidiasis
Aug 10, 2020 8:20am EDT SCYNEXIS Reports Second Quarter 2020 Financial Results and Provides Company Update
Jul 29, 2020 8:00am EDT SCYNEXIS Reports Successful Completion of Pre-NDA Meetings with the FDA Regarding Ibrexafungerp for the Treatment of Vulvovaginal Candidiasis
